Edward Owens is probably the best fund manager in health care sector. He reported the second quarter portfolios of his fund. These are the details of buys and sells.
Vanguard Health Care Fund lost 2.84% for the year. It averaged 5.68% annually for the past 10 years.
According to the most recent report of his fund, Vanguard Health Care Fund, Edward Owens owns 79 stocks with a total value of $16.7 billion. These are the details of the buys and sells.
This is the sector weightings of his portfolio:
These are the top 5 holdings of Edward Owens
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead Sciences Inc. has a market cap of $29.48 billion; its shares were traded at around $33.13 with a P/E ratio of 9.8 and P/S ratio of 4.2. Gilead Sciences Inc. had an annual average earning growth of 38.1% over the past 5 years.
Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnson & Johnson has a market cap of $160.93 billion; its shares were traded at around $58.72 with a P/E ratio of 12.4 and P/S ratio of 2.7. The dividend yield of Johnson & Johnson stocks is 3.6%. Johnson & Johnson had an annual average earning growth of 10.8% over the past 10 years. GuruFocus rated Johnson & Johnson the business predictability rank of 4.5-star.
Baxter engages in the worldwide development, manufacture and distribution of a diversified line of products, systems and services used primarily in the health-care field. Baxter International Inc. has a market cap of $26.92 billion; its shares were traded at around $44.99 with a P/E ratio of 11.6 and P/S ratio of 2.2. The dividend yield of Baxter International Inc. stocks is 2.6%. Baxter International Inc. had an annual average earning growth of 7.1% over the past 10 years. GuruFocus rated Baxter International Inc. the business predictability rank of 3.5-star.
IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Biogen Idec Inc has a market cap of $14.7 billion; its shares were traded at around $55.06 with a P/E ratio of 12 and P/S ratio of 3.4. Biogen Idec Inc had an annual average earning growth of 36.8% over the past 5 years.
GlaxoSmithKline is one of the world's research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Glaxosmithkline Plc has a market cap of $108.3 billion; its shares were traded at around $37.29 with a P/E ratio of 12.4 and P/S ratio of 2.5. The dividend yield of Glaxosmithkline Plc stocks is 5.2%. Glaxosmithkline Plc had an annual average earning growth of 6.8% over the past 10 years. GuruFocus rated Glaxosmithkline Plc the business predictability rank of 3-star.
Onyx Pharmaceuticals, Inc is developing innovative products for the treatment of cancer. Onyx Pharmaceuticals Inc. has a market cap of $1.63 billion; its shares were traded at around $26.04 with a P/E ratio of 153.2 and P/S ratio of 6.5.
UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. United Therapeutics Corp. has a market cap of $2.69 billion; its shares were traded at around $48.18 with a P/E ratio of 36.8 and P/S ratio of 7.2.
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron Pharmaceuticals Inc. has a market cap of $1.89 billion; its shares were traded at around $22.97 with and P/S ratio of 5.
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novonordisk A/s has a market cap of $52.99 billion; its shares were traded at around $85.88 with a P/E ratio of 23.8 and P/S ratio of 5.6. The dividend yield of Novonordisk A/s stocks is 1.1%.
Mead Johnson Nutrition Company is a pediatric nutrition company. Mead Johnson Nutriti has a market cap of $11.04 billion; its shares were traded at around $52.94 with a P/E ratio of 23.6 and P/S ratio of 3.9. The dividend yield of Mead Johnson Nutriti stocks is 1.7%.
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. Ironwood Pharmaceuticals Inc. has a market cap of $183.6 million; its shares were traded at around $9.58 .
Vanguard Health Care Fund lost 2.84% for the year. It averaged 5.68% annually for the past 10 years.
According to the most recent report of his fund, Vanguard Health Care Fund, Edward Owens owns 79 stocks with a total value of $16.7 billion. These are the details of the buys and sells.
- New Purchases: REGN,
- Added Positions: BAX, BIIB, GILD, GSK, JNJ, ONXX, UTHR,
- Reduced Positions: MJN, NVO,
- Sold Out: IRWD,
This is the sector weightings of his portfolio:
These are the top 5 holdings of Edward Owens
- Merck & Co. Inc. (MRK) - 33,830,248 shares, 7.09% of the total portfolio. Shares added by 0.59%
- Forest Laboratories Inc. (FRX) - 29,533,000 shares, 4.85% of the total portfolio. Shares reduced by 1.34%
- McKesson Corp. (MCK) - 11,089,900 shares, 4.46% of the total portfolio. Shares reduced by 0.89%
- AstraZeneca PLC (AZN) - 14,881,500 shares, 4.2% of the total portfolio.
- Eli Lilly And Company (LLY) - 19,879,900 shares, 3.99% of the total portfolio.
Added: Gilead Sciences Inc. (GILD, Financial)
Edward Owens added to his holdings in Gilead Sciences Inc. by 504.47%. His purchase prices were between $32.91 and $46.35, with an estimated average price of $38.89. The impact to his portfolio due to this purchase was 0.73%. His holdings were 4,231,300 shares as of 06/30/2010.Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead Sciences Inc. has a market cap of $29.48 billion; its shares were traded at around $33.13 with a P/E ratio of 9.8 and P/S ratio of 4.2. Gilead Sciences Inc. had an annual average earning growth of 38.1% over the past 5 years.
Added: Johnson & Johnson (JNJ, Financial)
Edward Owens added to his holdings in Johnson & Johnson by 28%. His purchase prices were between $58 and $66.03, with an estimated average price of $62.2. The impact to his portfolio due to this purchase was 0.49%. His holdings were 6,400,000 shares as of 06/30/2010.Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnson & Johnson has a market cap of $160.93 billion; its shares were traded at around $58.72 with a P/E ratio of 12.4 and P/S ratio of 2.7. The dividend yield of Johnson & Johnson stocks is 3.6%. Johnson & Johnson had an annual average earning growth of 10.8% over the past 10 years. GuruFocus rated Johnson & Johnson the business predictability rank of 4.5-star.
Added: Baxter International Inc. (BAX, Financial)
Edward Owens added to his holdings in Baxter International Inc. by 27.59%. His purchase prices were between $40.47 and $59.92, with an estimated average price of $46.72. The impact to his portfolio due to this purchase was 0.19%. His holdings were 3,700,000 shares as of 06/30/2010.Baxter engages in the worldwide development, manufacture and distribution of a diversified line of products, systems and services used primarily in the health-care field. Baxter International Inc. has a market cap of $26.92 billion; its shares were traded at around $44.99 with a P/E ratio of 11.6 and P/S ratio of 2.2. The dividend yield of Baxter International Inc. stocks is 2.6%. Baxter International Inc. had an annual average earning growth of 7.1% over the past 10 years. GuruFocus rated Baxter International Inc. the business predictability rank of 3.5-star.
Added: Biogen Idec Inc (BIIB, Financial)
Edward Owens added to his holdings in Biogen Idec Inc by 18.99%. His purchase prices were between $46.22 and $57.53, with an estimated average price of $51.03. The impact to his portfolio due to this purchase was 0.13%. His holdings were 2,820,000 shares as of 06/30/2010.IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Biogen Idec Inc has a market cap of $14.7 billion; its shares were traded at around $55.06 with a P/E ratio of 12 and P/S ratio of 3.4. Biogen Idec Inc had an annual average earning growth of 36.8% over the past 5 years.
Added: Glaxosmithkline Plc (GSK, Financial)
Edward Owens added to his holdings in Glaxosmithkline Plc by 20.59%. His purchase prices were between $32.34 and $39.57, with an estimated average price of $35.94. The impact to his portfolio due to this purchase was 0.08%. His holdings were 2,342,381 shares as of 06/30/2010.GlaxoSmithKline is one of the world's research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Glaxosmithkline Plc has a market cap of $108.3 billion; its shares were traded at around $37.29 with a P/E ratio of 12.4 and P/S ratio of 2.5. The dividend yield of Glaxosmithkline Plc stocks is 5.2%. Glaxosmithkline Plc had an annual average earning growth of 6.8% over the past 10 years. GuruFocus rated Glaxosmithkline Plc the business predictability rank of 3-star.
Added: Onyx Pharmaceuticals Inc. (ONXX, Financial)
Edward Owens added to his holdings in Onyx Pharmaceuticals Inc. by 61.03%. His purchase prices were between $21.7 and $31.18, with an estimated average price of $25.78. The impact to his portfolio due to this purchase was 0.06%. His holdings were 1,299,865 shares as of 06/30/2010.Onyx Pharmaceuticals, Inc is developing innovative products for the treatment of cancer. Onyx Pharmaceuticals Inc. has a market cap of $1.63 billion; its shares were traded at around $26.04 with a P/E ratio of 153.2 and P/S ratio of 6.5.
Added: United Therapeutics Corp. (UTHR, Financial)
Edward Owens added to his holdings in United Therapeutics Corp. by 45.05%. His purchase prices were between $49 and $58.49, with an estimated average price of $54.04. The impact to his portfolio due to this purchase was 0.03%. His holdings were 322,000 shares as of 06/30/2010.UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. United Therapeutics Corp. has a market cap of $2.69 billion; its shares were traded at around $48.18 with a P/E ratio of 36.8 and P/S ratio of 7.2.
New Purchase: Regeneron Pharmaceuticals Inc. (REGN, Financial)
Edward Owens initiated holdings in Regeneron Pharmaceuticals Inc.. His purchase prices were between $22.98 and $30.28, with an estimated average price of $26.36. The impact to his portfolio due to this purchase was 0.09%. His holdings were 700,000 shares as of 06/30/2010.Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron Pharmaceuticals Inc. has a market cap of $1.89 billion; its shares were traded at around $22.97 with and P/S ratio of 5.
Reduced: Novonordisk A/s (NVO, Financial)
Edward Owens reduced to his holdings in Novonordisk A/s by 42.86%. His sale prices were between $74.02 and $85.32, with an estimated average price of $79.87. The impact to his portfolio due to this sale was -0.08%. Edward Owens still held 400,000 shares as of 06/30/2010.Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novonordisk A/s has a market cap of $52.99 billion; its shares were traded at around $85.88 with a P/E ratio of 23.8 and P/S ratio of 5.6. The dividend yield of Novonordisk A/s stocks is 1.1%.
Reduced: Mead Johnson Nutriti (MJN, Financial)
Edward Owens reduced to his holdings in Mead Johnson Nutriti by 50.59%. His sale prices were between $47.61 and $54.39, with an estimated average price of $51.16. The impact to his portfolio due to this sale was -0.16%. Edward Owens still held 1,021,937 shares as of 06/30/2010.Mead Johnson Nutrition Company is a pediatric nutrition company. Mead Johnson Nutriti has a market cap of $11.04 billion; its shares were traded at around $52.94 with a P/E ratio of 23.6 and P/S ratio of 3.9. The dividend yield of Mead Johnson Nutriti stocks is 1.7%.
Sold Out: Ironwood Pharmaceuticals Inc. (IRWD, Financial)
Edward Owens sold out his holdings in Ironwood Pharmaceuticals Inc.. His sale prices were between $9.89 and $14.78, with an estimated average price of $12.72.Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. Ironwood Pharmaceuticals Inc. has a market cap of $183.6 million; its shares were traded at around $9.58 .
